Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Liraglutide
Drug ID BADD_D01298
Description Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist[Label,A6932]. Liraglutide is 97% homologous to native human GLP-1 by substituting arginine for lysine at position 34[A6932]. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor[A6932]. Liraglutide was granted FDA approval on Januray 25, 2010[L6070].
Indications and Usage Liraglutide is indicated in combination with diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus[Label,L6718]. It is also indicated to reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus as well as cardiovascular disease[Label].
Marketing Status approved
ATC Code A10BJ02
DrugBank ID DB06655
KEGG ID D06404
MeSH ID D000069450
PubChem ID 16134956
TTD Drug ID D03GOI
NDC Product Code 52221-122; 71052-126; 66558-0193; 50090-4503; 76177-118; 0420-9006; 41524-0011; 50090-2853; 65129-1375; 14403-0009; 69766-034; 0169-4060; 70155-003; 71796-022; 0169-2800; 32861-0003
UNII 839I73S42A
Synonyms Liraglutide | Victoza | Saxenda | NN 2211 | 2211, NN | NN2211 | NN-2211
Chemical Information
Molecular Formula C172H265N43O51
CAS Registry Number 204656-20-2
SMILES CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O) NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O )NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O )C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O )C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C( CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6) N)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dyspepsia07.01.02.001--
Dyspnoea02.11.05.003; 22.02.01.004--
Eructation07.01.02.003--
Erythema23.03.06.001---
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014---
Flatulence07.01.04.002--
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.003--
Gastroenteritis07.19.03.001; 11.01.07.004---
Gastroenteritis viral07.19.03.005; 11.05.04.005---
Gastrointestinal disorder07.11.01.001---
Gastrointestinal pain07.01.05.005--
Headache17.14.01.001--
Heart rate increased13.14.04.002---
Hepatitis09.01.07.004---
Hyperbilirubinaemia01.06.04.003; 09.01.01.003; 14.11.01.010---
Hypersensitivity10.01.03.003--
Hypoglycaemia05.06.03.001; 14.06.03.001--
Hypotension24.06.03.002--
Immune system disorder10.02.01.001---
Infection11.01.08.002---
Injection site dermatitis08.02.03.041; 12.07.03.041; 23.03.04.033---
Injection site erythema08.02.03.001; 12.07.03.001; 23.03.06.015---
Injection site reaction08.02.03.014; 12.07.03.015--
Insomnia17.15.03.002; 19.02.01.002--
Intestinal obstruction07.13.01.002---
Lipase increased13.05.01.003--
Malaise08.01.01.003--
Medullary thyroid cancer05.02.05.007; 16.24.03.004---
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages